Peptide Use Between and After Steroid Cycles

The Post-Cycle Problem We're Trying to Solve

Many lifters say the hardest part of an anabolic cycle isn't the injections. It's the end.

When the steroids stop, endogenous testosterone production has been suppressed, sometimes for months. During the cycle, the feedback loop connecting the brain (hypothalamus and pituitary) to the testes goes quiet. Users describe feeling weak and tired, with lower libido and mood, and they worry about losing the muscle they gained on cycle.

Human studies back up the suppression. In a 2015 study of 24 former long-term steroid users, five had testosterone below 200 ng/dL after 3-26 months off, and 29% had a major depressive episode during withdrawal. In a 2020 study of past users, mean recovery of LH took almost 11 months.

Traditional post-cycle therapy (PCT) using SERMs like Nolvadex (tamoxifen) or Clomid (clomiphene) is designed to restart the hypothalamic-pituitary-testicular axis (HPTA), but it's not instantaneous. The evidence behind it is also thin: a 2014 review in Fertility and Sterility set out to run a meta-analysis on treating steroid-induced hypogonadism and found no studies of enough quality to include.

This is where peptides come in. Growth hormone secretagogues (GHS) and healing peptides like BPC-157 work through different pathways than AAS and aren't known to suppress the testes, so some lifters use them during the transition, hoping to hold on to muscle while natural hormones get back online. As of October 2026, we found no human study that has tested any peptide for this purpose. Our peptides vs. anabolic steroids overview compares the two mechanisms in more depth.

The Two Scenarios: Bridging vs. PCT Support

Community guides split this into two situations: holding mass between two cycles, or coming off completely for a while. These are two different scenarios requiring two different plans.

Bridging: Holding Ground Between Blasts

A "bridge" is the period where someone is off heavy androgens but not fully "off." They stay on a TRT dose of testosterone and let their bloodwork normalize before the next cycle. The goal users describe is holding onto as much new muscle as possible, and a GHS stack is the most common add-on.

The combination users mention most is a GHRH analog, Mod GRF 1-29 (CJC-1295 without DAC), paired with a GHRP, ipamorelin. Mod GRF tells the pituitary to release growth hormone (GH), and ipamorelin amplifies that release through a different receptor. The result is a larger pulse of the body's own GH. Injected GH has human data: in a 2017 meta-analysis of 11 placebo-controlled trials in healthy young adults, it increased lean body mass and reduced fat mass but didn't improve strength. Nobody has measured whether a secretagogue-driven pulse during a bridge does the same.

Ipamorelin is popular because it's selective. In the 1998 animal studies that introduced it, ipamorelin raised GH in swine without raising cortisol, even at over 200 times the effective dose, while GHRP-2 and GHRP-6 raised cortisol. None changed prolactin. The human data are thinner. In a Phase 2 trial in 117 adults after abdominal surgery, the ipamorelin group had more low potassium, insomnia and high blood sugar than placebo, and the trial missed its primary endpoint, according to FDA's 2024 review. Surgical patients aren't healthy lifters, but "low on side effects" rests on animal data and user reports, not human trials. Our ipamorelin profile has the details.

PCT Support: The Soft Landing

If someone is coming off entirely and starting PCT with SERMs, the goal shifts from maintenance to recovering the HPTA. Many community guides say simplicity is key here, with fewer variables if something goes wrong.

Users commonly describe a standalone dose of ipamorelin, or a lower-dose Mod GRF/ipamorelin stack, before bed. The stated aim isn't building new tissue; it's a steady anti-catabolic signal to protect existing muscle while testosterone climbs back. That's plausible, but no study has measured muscle retention with a GH secretagogue during PCT.

Healing peptides like BPC-157 or TB-500 also come up. The reasoning in community guides is that when users come off cycle, strength often drops, but joints and tendons are still conditioned to the heavy loads they were just moving, so this is treated as a high-risk period for injuries. Some report running BPC-157 during the first 4-6 weeks of PCT. The support is almost all animal work, such as a 2008 rat study where BPC-157 sped healing after muscle crush injury. A 2025 systematic review found that 35 of 36 BPC-157 studies were preclinical, with no clinical safety data. TB-500 has no human data for the fragment itself. See our BPC-157 profile.

Practical Protocols: From Theory to Syringe

The table summarizes what users commonly report in forums and community guides. These aren't tested protocols: no trial has studied these peptides in people coming off steroids, and the only human ipamorelin doses come from IV studies dosed by body weight (0.03 mg/kg twice daily in the post-surgery Phase 2).

On timing, users commonly report injecting GHS peptides on an empty stomach and waiting 20-30 minutes before a meal, on the reasoning that insulin blunts the GH pulse. Many treat the bedtime dose as the most important, to match the body's natural GH pulse during deep sleep. No study has tested that timing for ipamorelin.

What About Tolerance and Cycling Off?

There's a lot of debate online about desensitization to GH secretagogues. Some users run them 5 days on, 2 days off; others say that's unnecessary for the Mod GRF/ipamorelin stack.

The clearest human data come from hexarelin, a stronger GHRP. In a 1998 study, 12 healthy older adults injected it twice daily for 16 weeks, and their GH response fell by about 45%, then recovered 4 weeks after stopping. We found no comparable study for ipamorelin or Mod GRF, so the forum claim that tolerance is minimal over an 8-16 week run is an extrapolation.

Many guides say the cycle structure should be dictated by AAS use, not the other way around: use the peptides for the duration they're needed, during the bridge or PCT, then drop them. No study has compared schedules.

What we still don't know

Peptides are not a replacement for a well-structured PCT using SERMs. They do not restart the HPTA: GH secretagogues act on the pituitary's GH output, not on the hormones that drive testosterone production. As of October 2026, no trial has tested whether they preserve muscle or strength after steroid withdrawal, and human ipamorelin data cover only IV use for up to 7 days after surgery. Whether BPC-157's rodent results carry over to human tendons hasn't been tested in a controlled trial.

For tested athletes, WADA's 2026 Prohibited List bans all of these at all times: ipamorelin, CJC-1295 and other GH secretagogues (S2.2.4), BPC-157 (S0), TB-500 (S2.3), and the SERMs used in PCT (S4.2). For health effects over years, see long-term effects of peptides vs. steroids.

Comparison table